Biodesix (BDSX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$102.9M

Revenue (quarter)

$26.9M

Revenue growth (year over year)

+34.18%

Gross profit (trailing twelve months)

$84.9M

Gross margin

82.50%

Net income (trailing twelve months)

−$27.8M

Net income (quarter)

−$7.3M

Net income growth (year over year)

+36.58%

Net margin

−26.97%

Return on equity

−540.01%

EPS (trailing twelve months)

−$3.10

Book value per share

$0.87

P/E (trailing twelve months)

—

Price to book

28.51

Debt to assets

90.41%

Payout ratio

—

Dividend yield

—

Company profile

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

• Is Biodesix (BDSX) profitable?

  No. Biodesix reported a net loss of $27.8M over the trailing twelve months.

• How much revenue does Biodesix (BDSX) make?

  Biodesix generated $102.9M in revenue over the trailing twelve months, up 34.18% year over year.

• How do I buy stock in Biodesix (BDSX)?

  BDSX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.